Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CRINETICS PHARMACEUTICALS, INC.

(CRNX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CRINETICS PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)

06/23/2021 | 04:57pm EDT

Item 5.07Submission of Matters to a Vote of Security Holders.

Crinetics Pharmaceuticals, Inc. (the "Company") held its annual meeting of stockholders on June 22, 2021. The following is a brief description of each matter voted upon at the meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable.



    1. The election of two directors to serve as Class III directors for a
       three-year term to expire at the 2024 annual meeting of stockholders. The
       following two Class III directors were re-elected by the votes indicated:




                            For      Withheld    Broker Non-Votes

Camille Bedrosian, M.D. 25,859,471 4,554,351 3,205,675 Wendell Wierenga, Ph.D. 30,379,916 33,906 3,205,675




    2. The ratification of the selection of BDO USA, LLP as the Company's
       independent registered public accounting firm for the fiscal year ending
       December 31, 2021. The selection was ratified by the votes indicated:




   For       Against   Abstain   Broker Non-Votes
33,616,813     83       2,601           0




                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about CRINETICS PHARMACEUTICALS, INC.
07/07Certain Common Stock of Crinetics Pharmaceuticals, Inc. are subject to a Lock..
CI
07/07Certain Options of Crinetics Pharmaceuticals, Inc. are subject to a Lock-Up A..
CI
06/28CRINETICS PHARMACEUTICALS : Doses First Patient in Phase 3 Trial of Acromegaly D..
MT
06/28CRINETICS PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
06/28Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFN..
GL
06/28Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFN..
CI
06/25CRINETICS PHARMACEUTICALS : Slider preview
PU
06/25CRINETICS PHARMACEUTICALS, INC.(NASD : CRNX) added to Russell Small Cap Comp Val..
CI
06/25CRINETICS PHARMACEUTICALS, INC.(NASD : CRNX) added to Russell Microcap Value Ind..
CI
06/25CRINETICS PHARMACEUTICALS, INC.(NASD : CRNX) added to Russell 3000E Value Index
CI
More news